AP2M1 and KCNJ11 |
adaptor-related protein complex 2, mu 1 subunit |
potassium channel, inwardly rectifying subfamily J, member 11 |
- Retrograde neurotrophin signalling
- Axon guidance
- Gap junction degradation
- HIV Infection
- Nef Mediated CD8 Down-regulation
- L1CAM interactions
- Signaling by Wnt
- Signaling by EGFRvIII in Cancer
- Recycling pathway of L1
- EPH-ephrin mediated repulsion of cells
- Gap junction trafficking and regulation
- MHC class II antigen presentation
- EPH-Ephrin signaling
- Nef Mediated CD4 Down-regulation
- EGFR downregulation
- Formation of annular gap junctions
- Signalling by NGF
- Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters
- Nef mediated downregulation of CD28 cell surface expression
- Gap junction trafficking
- Host Interactions of HIV factors
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- The role of Nef in HIV-1 replication and disease pathogenesis
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- beta-catenin independent WNT signaling
- Signaling by EGFR
- WNT5A-dependent internalization of FZD4
- Signaling by EGFR in Cancer
- PCP/CE pathway
- Adaptive Immune System
|
- Inwardly rectifying K+ channels
- Integration of energy metabolism
- ATP sensitive Potassium channels
- Regulation of insulin secretion
- Potassium Channels
|
|
- Glimepiride
- Ibutilide
- Verapamil
- Levosimendan
- Glyburide
- Diazoxide
- Thiamylal
|
|
|
AP2M1 and CTLA4 |
adaptor-related protein complex 2, mu 1 subunit |
cytotoxic T-lymphocyte-associated protein 4 |
- Retrograde neurotrophin signalling
- Axon guidance
- Gap junction degradation
- HIV Infection
- Nef Mediated CD8 Down-regulation
- L1CAM interactions
- Signaling by Wnt
- Signaling by EGFRvIII in Cancer
- Recycling pathway of L1
- EPH-ephrin mediated repulsion of cells
- Gap junction trafficking and regulation
- MHC class II antigen presentation
- EPH-Ephrin signaling
- Nef Mediated CD4 Down-regulation
- EGFR downregulation
- Formation of annular gap junctions
- Signalling by NGF
- Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters
- Nef mediated downregulation of CD28 cell surface expression
- Gap junction trafficking
- Host Interactions of HIV factors
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- The role of Nef in HIV-1 replication and disease pathogenesis
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- beta-catenin independent WNT signaling
- Signaling by EGFR
- WNT5A-dependent internalization of FZD4
- Signaling by EGFR in Cancer
- PCP/CE pathway
- Adaptive Immune System
|
- Costimulation by the CD28 family
- CTLA4 inhibitory signaling
- Adaptive Immune System
|
|
|
|
|
CNTN1 and NOTCH2 |
contactin 1 |
notch 2 |
- Signaling by NOTCH1 HD Domain Mutants in Cancer
- Axon guidance
- Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
- Signaling by NOTCH
- L1CAM interactions
- NOTCH2 Activation and Transmission of Signal to the Nucleus
- Activated NOTCH1 Transmits Signal to the Nucleus
- Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
- Signaling by NOTCH2
- Neurofascin interactions
- Signaling by NOTCH1
- Signaling by NOTCH1 PEST Domain Mutants in Cancer
- Signaling by NOTCH1 in Cancer
- FBXW7 Mutants and NOTCH1 in Cancer
|
- Notch-HLH transcription pathway
- Signaling by NOTCH2
- Generic Transcription Pathway
- Pre-NOTCH Processing in Golgi
- Pre-NOTCH Transcription and Translation
- Signaling by NOTCH
- Pre-NOTCH Processing in the Endoplasmic Reticulum
- Pre-NOTCH Expression and Processing
- NOTCH2 intracellular domain regulates transcription
- NOTCH2 Activation and Transmission of Signal to the Nucleus
|
|
|
|
|
COPA and MTNR1B |
coatomer protein complex, subunit alpha |
melatonin receptor 1B |
- COPI Mediated Transport
- Golgi to ER Retrograde Transport
|
- Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
- Signaling by GPCR
- GPCR downstream signaling
- Class A/1 (Rhodopsin-like receptors)
- G alpha (i) signalling events
- Metabolic disorders of biological oxidation enzymes
- GPCR ligand binding
|
|
- Ramelteon
- Melatonin
- Agomelatine
|
|
|
CPE and INS |
carboxypeptidase E |
insulin |
- Peptide hormone metabolism
- Insulin processing
|
- Synthesis, secretion, and deacylation of Ghrelin
- Insulin receptor signalling cascade
- Integration of energy metabolism
- Regulation of insulin secretion
- IRS-related events
- SHC-related events
- Insulin receptor recycling
- Peptide hormone metabolism
- IRS activation
- Regulation of beta-cell development
- Signal attenuation
- Regulation of gene expression in beta cells
- Insulin processing
- SHC activation
- Signaling by Insulin receptor
|
- Insulin Regular
- Insulin, porcine
|
|
|
|
CREB1 and HNF1B |
cAMP responsive element binding protein 1 |
HNF1 homeobox B |
- Signaling by the B Cell Receptor (BCR)
- Ca-dependent events
- Signaling by GPCR
- CaM pathway
- Phospholipase C-mediated cascade
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- CREB phosphorylation through the activation of Ras
- PLCG1 events in ERBB2 signaling
- NOTCH2 intracellular domain regulates transcription
- Signaling by SCF-KIT
- Toll Like Receptor TLR1:TLR2 Cascade
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- Signaling by NOTCH2
- PI3K/AKT activation
- Toll Like Receptor 5 (TLR5) Cascade
- PI-3K cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- MyD88 dependent cascade initiated on endosome
- Toll Like Receptor 9 (TLR9) Cascade
- Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
- Signaling by PDGF
- Calmodulin induced events
- CaMK IV-mediated phosphorylation of CREB
- DAP12 interactions
- PKA-mediated phosphorylation of CREB
- GAB1 signalosome
- Signaling by NOTCH
- TRIF-mediated TLR3/TLR4 signaling
- Opioid Signalling
- Signaling by ERBB4
- Role of LAT2/NTAL/LAB on calcium mobilization
- Constitutive PI3K/AKT Signaling in Cancer
- PI3K events in ERBB4 signaling
- CREB phosphorylation through the activation of Adenylate Cyclase
- EGFR interacts with phospholipase C-gamma
- CaMK IV-mediated phosphorylation of CREB
- Toll Like Receptor 2 (TLR2) Cascade
- Signaling by ERBB2
- PKA-mediated phosphorylation of CREB
- Signaling by EGFR
- CREB phosphorylation through the activation of CaMKK
- AKT phosphorylates targets in the nucleus
- Calmodulin induced events
- Toll Like Receptor 4 (TLR4) Cascade
- Toll Like Receptor 3 (TLR3) Cascade
- Downstream signal transduction
- CREB phosphorylation through the activation of CaMKII
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- PI3K/AKT Signaling in Cancer
- Transcriptional activation of mitochondrial biogenesis
- Transmission across Chemical Synapses
- Adaptive Immune System
- Organelle biogenesis and maintenance
- CREB phosphorylation
- Axon guidance
- PIP3 activates AKT signaling
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- CREB phosphorylation
- DAG and IP3 signaling
- Toll Like Receptor TLR6:TLR2 Cascade
- CaM pathway
- Activated TLR4 signalling
- MyD88 cascade initiated on plasma membrane
- PI3K events in ERBB2 signaling
- Activation of NMDA receptor upon glutamate binding and postsynaptic events
- Downstream signaling of activated FGFR
- MyD88:Mal cascade initiated on plasma membrane
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- NCAM signaling for neurite out-growth
- Post NMDA receptor activation events
- Innate Immune System
- Signalling by NGF
- PLC beta mediated events
- MAP kinase activation in TLR cascade
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- G-protein mediated events
- NGF signalling via TRKA from the plasma membrane
- MyD88-independent cascade
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Mitochondrial biogenesis
- Signaling by FGFR
- Toll-Like Receptors Cascades
- Toll Like Receptor 10 (TLR10) Cascade
- PLC-gamma1 signalling
- MAPK targets/ Nuclear events mediated by MAP kinases
- Nuclear Events (kinase and transcription factor activation)
|
- Regulation of beta-cell development
- Regulation of gene expression in early pancreatic precursor cells
- Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells
|
- Adenosine monophosphate
- Naloxone
|
|
|
|
CREBBP and PPARG |
CREB binding protein |
peroxisome proliferator-activated receptor gamma |
- Signaling by NOTCH1 HD Domain Mutants in Cancer
- Metabolism of lipids and lipoproteins
- Signaling by Wnt
- Regulation of gene expression by Hypoxia-inducible Factor
- Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
- Generic Transcription Pathway
- Pre-NOTCH Transcription and Translation
- RNF mutants show enhanced WNT signaling and proliferation
- Signaling by NOTCH1 in Cancer
- Orphan transporters
- Chromatin organization
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- Signaling by NOTCH
- formation of the beta-catenin:TCF transactivating complex
- Factors involved in megakaryocyte development and platelet production
- Chromatin modifying enzymes
- LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
- Signaling by NOTCH1 PEST Domain Mutants in Cancer
- Activation of gene expression by SREBF (SREBP)
- Transcriptional activation of mitochondrial biogenesis
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- PPARA activates gene expression
- Cellular response to hypoxia
- Organelle biogenesis and maintenance
- Regulation of Hypoxia-inducible Factor (HIF) by oxygen
- Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
- Attenuation phase
- HATs acetylate histones
- RORA activates circadian gene expression
- Regulation of cholesterol biosynthesis by SREBP (SREBF)
- HSF1-dependent transactivation
- TRAF3-dependent IRF activation pathway
- Signaling by NOTCH1
- Transcriptional regulation of white adipocyte differentiation
- XAV939 inhibits tankyrase, stabilizing AXIN
- Pre-NOTCH Expression and Processing
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- Innate Immune System
- FBXW7 Mutants and NOTCH1 in Cancer
- Fatty acid, triacylglycerol, and ketone body metabolism
- Cytosolic sensors of pathogen-associated DNA
- Cellular response to heat stress
- REV-ERBA represses gene expression
- Mitochondrial biogenesis
- Notch-HLH transcription pathway
- RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
- NOTCH1 Intracellular Domain Regulates Transcription
- TCF dependent signaling in response to WNT
- TRAF6 mediated IRF7 activation
- YAP1- and WWTR1 (TAZ)-stimulated gene expression
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
- Signaling by WNT in cancer
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
|
- PPARA activates gene expression
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Generic Transcription Pathway
- Transcriptional regulation of white adipocyte differentiation
- Nuclear Receptor transcription pathway
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
|
|
- Icosapent
- Troglitazone
- Mesalazine
- Indomethacin
- Rosiglitazone
- Nateglinide
- Sulfasalazine
- Repaglinide
- Telmisartan
- Balsalazide
- Ibuprofen
- Glipizide
- Pioglitazone
- Mitiglinide
- Bezafibrate
- (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
- 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
- (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
- 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
- (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
- (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
- (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
- (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
- difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
- (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
- 3-(5-methoxy-1H-indol-3-yl)propanoic acid
- 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
- (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
- 2-chloro-5-nitro-N-phenylbenzamide
- (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
- 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
- 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
- (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
- 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
- (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
- ALEGLITAZAR
|
|
|
CREBBP and HNF4A |
CREB binding protein |
hepatocyte nuclear factor 4, alpha |
- Signaling by NOTCH1 HD Domain Mutants in Cancer
- Metabolism of lipids and lipoproteins
- Signaling by Wnt
- Regulation of gene expression by Hypoxia-inducible Factor
- Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
- Generic Transcription Pathway
- Pre-NOTCH Transcription and Translation
- RNF mutants show enhanced WNT signaling and proliferation
- Signaling by NOTCH1 in Cancer
- Orphan transporters
- Chromatin organization
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- Signaling by NOTCH
- formation of the beta-catenin:TCF transactivating complex
- Factors involved in megakaryocyte development and platelet production
- Chromatin modifying enzymes
- LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
- Signaling by NOTCH1 PEST Domain Mutants in Cancer
- Activation of gene expression by SREBF (SREBP)
- Transcriptional activation of mitochondrial biogenesis
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- PPARA activates gene expression
- Cellular response to hypoxia
- Organelle biogenesis and maintenance
- Regulation of Hypoxia-inducible Factor (HIF) by oxygen
- Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
- Attenuation phase
- HATs acetylate histones
- RORA activates circadian gene expression
- Regulation of cholesterol biosynthesis by SREBP (SREBF)
- HSF1-dependent transactivation
- TRAF3-dependent IRF activation pathway
- Signaling by NOTCH1
- Transcriptional regulation of white adipocyte differentiation
- XAV939 inhibits tankyrase, stabilizing AXIN
- Pre-NOTCH Expression and Processing
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- Innate Immune System
- FBXW7 Mutants and NOTCH1 in Cancer
- Fatty acid, triacylglycerol, and ketone body metabolism
- Cytosolic sensors of pathogen-associated DNA
- Cellular response to heat stress
- REV-ERBA represses gene expression
- Mitochondrial biogenesis
- Notch-HLH transcription pathway
- RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
- NOTCH1 Intracellular Domain Regulates Transcription
- TCF dependent signaling in response to WNT
- TRAF6 mediated IRF7 activation
- YAP1- and WWTR1 (TAZ)-stimulated gene expression
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
- Signaling by WNT in cancer
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
|
- Generic Transcription Pathway
- Nuclear Receptor transcription pathway
|
|
|
|
|
CREBBP and HNF1A |
CREB binding protein |
HNF1 homeobox A |
- Signaling by NOTCH1 HD Domain Mutants in Cancer
- Metabolism of lipids and lipoproteins
- Signaling by Wnt
- Regulation of gene expression by Hypoxia-inducible Factor
- Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
- Generic Transcription Pathway
- Pre-NOTCH Transcription and Translation
- RNF mutants show enhanced WNT signaling and proliferation
- Signaling by NOTCH1 in Cancer
- Orphan transporters
- Chromatin organization
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- Signaling by NOTCH
- formation of the beta-catenin:TCF transactivating complex
- Factors involved in megakaryocyte development and platelet production
- Chromatin modifying enzymes
- LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
- Signaling by NOTCH1 PEST Domain Mutants in Cancer
- Activation of gene expression by SREBF (SREBP)
- Transcriptional activation of mitochondrial biogenesis
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- PPARA activates gene expression
- Cellular response to hypoxia
- Organelle biogenesis and maintenance
- Regulation of Hypoxia-inducible Factor (HIF) by oxygen
- Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
- Attenuation phase
- HATs acetylate histones
- RORA activates circadian gene expression
- Regulation of cholesterol biosynthesis by SREBP (SREBF)
- HSF1-dependent transactivation
- TRAF3-dependent IRF activation pathway
- Signaling by NOTCH1
- Transcriptional regulation of white adipocyte differentiation
- XAV939 inhibits tankyrase, stabilizing AXIN
- Pre-NOTCH Expression and Processing
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- Innate Immune System
- FBXW7 Mutants and NOTCH1 in Cancer
- Fatty acid, triacylglycerol, and ketone body metabolism
- Cytosolic sensors of pathogen-associated DNA
- Cellular response to heat stress
- REV-ERBA represses gene expression
- Mitochondrial biogenesis
- Notch-HLH transcription pathway
- RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
- NOTCH1 Intracellular Domain Regulates Transcription
- TCF dependent signaling in response to WNT
- TRAF6 mediated IRF7 activation
- YAP1- and WWTR1 (TAZ)-stimulated gene expression
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
- Signaling by WNT in cancer
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
|
- Regulation of beta-cell development
- Regulation of gene expression in beta cells
|
|
|
|
|
CREBBP and HNF1B |
CREB binding protein |
HNF1 homeobox B |
- Signaling by NOTCH1 HD Domain Mutants in Cancer
- Metabolism of lipids and lipoproteins
- Signaling by Wnt
- Regulation of gene expression by Hypoxia-inducible Factor
- Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
- Generic Transcription Pathway
- Pre-NOTCH Transcription and Translation
- RNF mutants show enhanced WNT signaling and proliferation
- Signaling by NOTCH1 in Cancer
- Orphan transporters
- Chromatin organization
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- Signaling by NOTCH
- formation of the beta-catenin:TCF transactivating complex
- Factors involved in megakaryocyte development and platelet production
- Chromatin modifying enzymes
- LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
- Signaling by NOTCH1 PEST Domain Mutants in Cancer
- Activation of gene expression by SREBF (SREBP)
- Transcriptional activation of mitochondrial biogenesis
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- PPARA activates gene expression
- Cellular response to hypoxia
- Organelle biogenesis and maintenance
- Regulation of Hypoxia-inducible Factor (HIF) by oxygen
- Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
- Attenuation phase
- HATs acetylate histones
- RORA activates circadian gene expression
- Regulation of cholesterol biosynthesis by SREBP (SREBF)
- HSF1-dependent transactivation
- TRAF3-dependent IRF activation pathway
- Signaling by NOTCH1
- Transcriptional regulation of white adipocyte differentiation
- XAV939 inhibits tankyrase, stabilizing AXIN
- Pre-NOTCH Expression and Processing
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- Innate Immune System
- FBXW7 Mutants and NOTCH1 in Cancer
- Fatty acid, triacylglycerol, and ketone body metabolism
- Cytosolic sensors of pathogen-associated DNA
- Cellular response to heat stress
- REV-ERBA represses gene expression
- Mitochondrial biogenesis
- Notch-HLH transcription pathway
- RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
- NOTCH1 Intracellular Domain Regulates Transcription
- TCF dependent signaling in response to WNT
- TRAF6 mediated IRF7 activation
- YAP1- and WWTR1 (TAZ)-stimulated gene expression
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
- Signaling by WNT in cancer
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
|
- Regulation of beta-cell development
- Regulation of gene expression in early pancreatic precursor cells
- Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells
|
|
|
|
|
CRK and ERBB3 |
v-crk avian sarcoma virus CT10 oncogene homolog |
erb-b2 receptor tyrosine kinase 3 |
- Signalling to ERKs
- Prolonged ERK activation events
- Platelet Aggregation (Plug Formation)
- VEGFA-VEGFR2 Pathway
- Regulation of signaling by CBL
- Fcgamma receptor (FCGR) dependent phagocytosis
- Regulation of actin dynamics for phagocytic cup formation
- Signaling by Insulin receptor
- Innate Immune System
- Signaling by PDGF
- Signalling by NGF
- Insulin receptor signalling cascade
- p130Cas linkage to MAPK signaling for integrins
- Integrin alphaIIb beta3 signaling
- Cytokine Signaling in Immune system
- NGF signalling via TRKA from the plasma membrane
- ARMS-mediated activation
- Signaling by Interleukins
- Signal attenuation
- Signaling by VEGF
- Downstream signal transduction
- Platelet activation, signaling and aggregation
- Interleukin-3, 5 and GM-CSF signaling
|
|
|
|
|
|
CRKL and ERBB3 |
v-crk avian sarcoma virus CT10 oncogene homolog-like |
erb-b2 receptor tyrosine kinase 3 |
- Signaling by PDGF
- Signalling to ERKs
- Signalling by NGF
- Prolonged ERK activation events
- Signaling by Interleukins
- Downstream signal transduction
- Regulation of signaling by CBL
- Cytokine Signaling in Immune system
- NGF signalling via TRKA from the plasma membrane
- Interleukin-3, 5 and GM-CSF signaling
- Frs2-mediated activation
|
|
|
|
|
|
CRKL and NOTCH2 |
v-crk avian sarcoma virus CT10 oncogene homolog-like |
notch 2 |
- Signaling by PDGF
- Signalling to ERKs
- Signalling by NGF
- Prolonged ERK activation events
- Signaling by Interleukins
- Downstream signal transduction
- Regulation of signaling by CBL
- Cytokine Signaling in Immune system
- NGF signalling via TRKA from the plasma membrane
- Interleukin-3, 5 and GM-CSF signaling
- Frs2-mediated activation
|
- Notch-HLH transcription pathway
- Signaling by NOTCH2
- Generic Transcription Pathway
- Pre-NOTCH Processing in Golgi
- Pre-NOTCH Transcription and Translation
- Signaling by NOTCH
- Pre-NOTCH Processing in the Endoplasmic Reticulum
- Pre-NOTCH Expression and Processing
- NOTCH2 intracellular domain regulates transcription
- NOTCH2 Activation and Transmission of Signal to the Nucleus
|
|
|
|
|
CRYAB and INS |
crystallin, alpha B |
insulin |
|
- Synthesis, secretion, and deacylation of Ghrelin
- Insulin receptor signalling cascade
- Integration of energy metabolism
- Regulation of insulin secretion
- IRS-related events
- SHC-related events
- Insulin receptor recycling
- Peptide hormone metabolism
- IRS activation
- Regulation of beta-cell development
- Signal attenuation
- Regulation of gene expression in beta cells
- Insulin processing
- SHC activation
- Signaling by Insulin receptor
|
|
|
|
|
MAPK14 and HNF4A |
mitogen-activated protein kinase 14 |
hepatocyte nuclear factor 4, alpha |
- ADP signalling through P2Y purinoceptor 1
- Cellular Senescence
- Toll Like Receptor TLR1:TLR2 Cascade
- Toll Like Receptor 5 (TLR5) Cascade
- NOD1/2 Signaling Pathway
- p38MAPK events
- MyD88 dependent cascade initiated on endosome
- Toll Like Receptor 9 (TLR9) Cascade
- ERK/MAPK targets
- activated TAK1 mediates p38 MAPK activation
- Regulation of mRNA stability by proteins that bind AU-rich elements
- CDO in myogenesis
- TRIF-mediated TLR3/TLR4 signaling
- Toll Like Receptor 2 (TLR2) Cascade
- Platelet homeostasis
- Activation of PPARGC1A (PGC-1alpha) by phosphorylation
- Myogenesis
- Signaling by VEGF
- Platelet sensitization by LDL
- Signalling to RAS
- Toll Like Receptor 4 (TLR4) Cascade
- Toll Like Receptor 3 (TLR3) Cascade
- Platelet activation, signaling and aggregation
- Signalling to ERKs
- Organelle biogenesis and maintenance
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- Signal amplification
- VEGFA-VEGFR2 Pathway
- Toll Like Receptor TLR6:TLR2 Cascade
- Activated TLR4 signalling
- Activation of the AP-1 family of transcription factors
- MyD88 cascade initiated on plasma membrane
- MyD88:Mal cascade initiated on plasma membrane
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- Innate Immune System
- Signalling by NGF
- MAP kinase activation in TLR cascade
- NGF signalling via TRKA from the plasma membrane
- MyD88-independent cascade
- Mitochondrial biogenesis
- Toll-Like Receptors Cascades
- Toll Like Receptor 10 (TLR10) Cascade
- DSCAM interactions
- KSRP destabilizes mRNA
- Oxidative Stress Induced Senescence
- Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
- ERK/MAPK targets
- MAPK targets/ Nuclear events mediated by MAP kinases
- Nuclear Events (kinase and transcription factor activation)
|
- Generic Transcription Pathway
- Nuclear Receptor transcription pathway
|
- 4-[5-[2-(1-Phenyl-Ethylamino)-Pyrimidin-4-Yl]-1-Methyl-4-(3-Trifluoromethylphenyl)-1h-Imidazol-2-Yl]-Piperidine
- N-[(3z)-5-Tert-Butyl-2-Phenyl-1,2-Dihydro-3h-Pyrazol-3-Ylidene]-N\'-(4-Chlorophenyl)Urea
- 1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperidin-4-Yl-3,4-Dihydroquinolin-2(1h)-One
- Inhibitor of P38 Kinase
- 6((S)-3-Benzylpiperazin-1-Yl)-3-(Naphthalen-2-Yl)-4-(Pyridin-4-Yl)Pyrazine
- 3-(4-Fluorophenyl)-1-Hydroxy-2-(Pyridin-4-Yl)-1h-Pyrrolo[3,2-B]Pyridine
- 1-(5-Tert-Butyl-2-Methyl-2h-Pyrazol-3-Yl)-3-(4-Chloro-Phenyl)-Urea
- 3-(Benzyloxy)Pyridin-2-Amine
- 1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperazin-1-Yl-3,4-Dihydroquinazolin-2(1h)-One
- 4-[3-Methylsulfanylanilino]-6,7-Dimethoxyquinazoline
- 1-(5-Tert-Butyl-2-P-Tolyl-2h-Pyrazol-3-Yl)-3-[4-(2-Morpholin-4-Yl-Ethoxy)-Naphthalen-1-Yl]-Urea
- 2-Chlorophenol
- 4-(Fluorophenyl)-1-Cyclopropylmethyl-5-(2-Amino-4-Pyrimidinyl)Imidazole
- SB220025
- 4-(2-HYDROXYBENZYLAMINO)-N-(3-(4-FLUOROPHENOXY)PHENYL)PIPERIDINE-1-SULFONAMIDE
- Triazolopyridine
- 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
- N-ethyl-4-{[5-(methoxycarbamoyl)-2-methylphenyl]amino}-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide
- N-[2-methyl-5-(methylcarbamoyl)phenyl]-2-{[(1R)-1-methylpropyl]amino}-1,3-thiazole-5-carboxamide
- 5-(2,6-dichlorophenyl)-2-[(2,4-difluorophenyl)sulfanyl]-6H-pyrimido[1,6-b]pyridazin-6-one
- N-cyclopropyl-4-methyl-3-[1-(2-methylphenyl)phthalazin-6-yl]benzamide
- 4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE
- 4-[5-(3-IODO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-1H-IMIDAZOL-4-YL]-PYRIDINE
- N-cyclopropyl-2\',6-dimethyl-4\'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-3-carboxamide
- 4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDINE
- 4-{4-[(5-hydroxy-2-methylphenyl)amino]quinolin-7-yl}-1,3-thiazole-2-carbaldehyde
- N-(3-cyanophenyl)-2\'-methyl-5\'-(5-methyl-1,3,4-oxadiazol-2-yl)-4-biphenylcarboxamide
- N-(cyclopropylmethyl)-2\'-methyl-5\'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide
- N~3~-cyclopropyl-N~4~\'-(cyclopropylmethyl)-6-methylbiphenyl-3,4\'-dicarboxamide
- 3-{3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxopyridin-1(2H)-yl}-N,4-dimethylbenzamide
- 2-fluoro-4-[4-(4-fluorophenyl)-1H-pyrazol-3-yl]pyridine
- 2-{4-[5-(4-chlorophenyl)-4-pyrimidin-4-yl-1H-pyrazol-3-yl]piperidin-1-yl}-2-oxoethanol
- N-(3-TERT-BUTYL-1H-PYRAZOL-5-YL)-N\'-{4-CHLORO-3-[(PYRIDIN-3-YLOXY)METHYL]PHENYL}UREA
- N-[4-CHLORO-3-(PYRIDIN-3-YLOXYMETHYL)-PHENYL]-3-FLUORO-
- 3-FLUORO-5-MORPHOLIN-4-YL-N-[3-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-5-YL]BENZAMIDE
- 3-FLUORO-N-1H-INDOL-5-YL-5-MORPHOLIN-4-YLBENZAMIDE
- 3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE
- 3-(2-CHLOROPHENYL)-1-(2-{[(1S)-2-HYDROXY-1,2-DIMETHYLPROPYL]AMINO}PYRIMIDIN-4-YL)-1-(4-METHOXYPHENYL)UREA
- 8-(2-CHLOROPHENYLAMINO)-2-(2,6-DIFLUOROPHENYLAMINO)-9-ETHYL-9H-PURINE-1,7-DIIUM
- 2-(2,6-DIFLUOROPHENOXY)-N-(2-FLUOROPHENYL)-9-ISOPROPYL-9H-PURIN-8-AMINE
- N,4-dimethyl-3-[(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino]benzamide
- N-cyclopropyl-3-{[1-(2,4-difluorophenyl)-7-methyl-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridin-4-yl]amino}-4-methylbenzamide
- N-cyclopropyl-4-methyl-3-{2-[(2-morpholin-4-ylethyl)amino]quinazolin-6-yl}benzamide
- 6-[4-(2-fluorophenyl)-1,3-oxazol-5-yl]-N-(1-methylethyl)-1,3-benzothiazol-2-amine
- 2-(ETHOXYMETHYL)-4-(4-FLUOROPHENYL)-3-[2-(2-HYDROXYPHENOXY)PYRIMIDIN-4-YL]ISOXAZOL-5(2H)-ONE
- [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL][3-(PIPERIDIN-4-YLOXY)PHENYL]METHANONE
- [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL](3-{[(2R)-2,3-DIHYDROXYPROPYL]OXY}PHENYL)METHANONE
- 4-[5-(4-FLUORO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-3H-IMIDAZOL-4-YL]-PYRIDINE
- 4-(4-FLUOROPHENYL)-1-CYCLOROPROPYLMETHYL-5-(4-PYRIDYL)-IMIDAZOLE
- 3-FLUORO-5-MORPHOLIN-4-YL-N-[1-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-6-YL]BENZAMIDE
|
|
|
|
CSK and PTPN22 |
c-src tyrosine kinase |
protein tyrosine phosphatase, non-receptor type 22 (lymphoid) |
- Costimulation by the CD28 family
- GAB1 signalosome
- Integrin alphaIIb beta3 signaling
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- Signaling by EGFRvIII in Cancer
- Platelet Aggregation (Plug Formation)
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by EGFR
- TCR signaling
- Signaling by EGFR in Cancer
- PD-1 signaling
- Platelet activation, signaling and aggregation
- Phosphorylation of CD3 and TCR zeta chains
- Adaptive Immune System
|
|
|
|
|
|
CSNK2A1 and TCF7L2 |
casein kinase 2, alpha 1 polypeptide |
transcription factor 7-like 2 (T-cell specific, HMG-box) |
- Mitotic Prometaphase
- Signal transduction by L1
- Axon guidance
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- L1CAM interactions
- Signaling by Wnt
- Cell Cycle, Mitotic
- M Phase
- WNT mediated activation of DVL
- TCF dependent signaling in response to WNT
- RNF mutants show enhanced WNT signaling and proliferation
- XAV939 inhibits tankyrase, stabilizing AXIN
- Signaling by WNT in cancer
- Condensation of Prometaphase Chromosomes
|
- APC truncation mutants have impaired AXIN binding
- misspliced GSK3beta mutants stabilize beta-catenin
- T41 mutants of beta-catenin aren't phosphorylated
- TCF7L2 mutants don't bind CTBP
- truncated APC mutants destabilize the destruction complex
- Signaling by Wnt
- binding of TCF/LEF:CTNNB1 to target gene promoters
- deactivation of the beta-catenin transactivating complex
- APC truncation mutants are not K63 polyubiquitinated
- S37 mutants of beta-catenin aren't phosphorylated
- Peptide hormone metabolism
- Degradation of beta-catenin by the destruction complex
- S33 mutants of beta-catenin aren't phosphorylated
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- RNF mutants show enhanced WNT signaling and proliferation
- XAV939 inhibits tankyrase, stabilizing AXIN
- Incretin synthesis, secretion, and inactivation
- truncations of AMER1 destabilize the destruction complex
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- formation of the beta-catenin:TCF transactivating complex
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- AXIN missense mutants destabilize the destruction complex
- S45 mutants of beta-catenin aren't phosphorylated
- repression of WNT target genes
- beta-catenin independent WNT signaling
- deletions in the AMER1 gene destabilize the destruction complex
- Ca2+ pathway
- AMER1 mutants destabilize the destruction complex
- TCF dependent signaling in response to WNT
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- Signaling by WNT in cancer
- Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)
|
- (5-Oxo-5,6-Dihydro-Indolo[1,2-a]Quinazolin-7-Yl)-Acetic Acid
- 1,8-Di-Hydroxy-4-Nitro-Xanthen-9-One
- Resveratrol
- 1,8-Di-Hydroxy-4-Nitro-Anthraquinone
- Benzamidine
- 5,8-Di-Amino-1,4-Dihydroxy-Anthraquinone
- Phosphoaminophosphonic Acid-Adenylate Ester
- Tetrabromo-2-Benzotriazole
- DIMETHYL-(4,5,6,7-TETRABROMO-1H-BENZOIMIDAZOL-2-YL)-AMINE
- S-METHYL-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
- N1,N2-ETHYLENE-2-METHYLAMINO-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
- 3-METHYL-1,6,8-TRIHYDROXYANTHRAQUINONE
- 3,8-DIBROMO-7-HYDROXY-4-METHYL-2H-CHROMEN-2-ONE
- 19-(cyclopropylamino)-4,6,7,15-tetrahydro-5H-16,1-(azenometheno)-10,14-(metheno)pyrazolo[4,3-o][1,3,9]triazacyclohexadecin-8(9H)-one
- N,N\'-DIPHENYLPYRAZOLO[1,5-A][1,3,5]TRIAZINE-2,4-DIAMINE
- 4-(2-(1H-IMIDAZOL-4-YL)ETHYLAMINO)-2-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
- 2-(CYCLOHEXYLMETHYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
- 2-(4-CHLOROBENZYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
- 2-(4-ETHYLPIPERAZIN-1-YL)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
- N-(3-(8-CYANO-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZIN-2-YLAMINO)PHENYL)ACETAMIDE
- 2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione
- 5,6-dichloro-1-beta-D-ribofuranosyl-1H-benzimidazole
- 1,2,5,8-tetrahydroxyanthracene-9,10-dione
- Ellagic Acid
|
|
|
|
CSNK2A2 and TCF7L2 |
casein kinase 2, alpha prime polypeptide |
transcription factor 7-like 2 (T-cell specific, HMG-box) |
- Mitotic Prometaphase
- Signal transduction by L1
- Axon guidance
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- L1CAM interactions
- Signaling by Wnt
- Cell Cycle, Mitotic
- M Phase
- WNT mediated activation of DVL
- TCF dependent signaling in response to WNT
- RNF mutants show enhanced WNT signaling and proliferation
- XAV939 inhibits tankyrase, stabilizing AXIN
- Signaling by WNT in cancer
- Condensation of Prometaphase Chromosomes
|
- APC truncation mutants have impaired AXIN binding
- misspliced GSK3beta mutants stabilize beta-catenin
- T41 mutants of beta-catenin aren't phosphorylated
- TCF7L2 mutants don't bind CTBP
- truncated APC mutants destabilize the destruction complex
- Signaling by Wnt
- binding of TCF/LEF:CTNNB1 to target gene promoters
- deactivation of the beta-catenin transactivating complex
- APC truncation mutants are not K63 polyubiquitinated
- S37 mutants of beta-catenin aren't phosphorylated
- Peptide hormone metabolism
- Degradation of beta-catenin by the destruction complex
- S33 mutants of beta-catenin aren't phosphorylated
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- RNF mutants show enhanced WNT signaling and proliferation
- XAV939 inhibits tankyrase, stabilizing AXIN
- Incretin synthesis, secretion, and inactivation
- truncations of AMER1 destabilize the destruction complex
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- formation of the beta-catenin:TCF transactivating complex
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- AXIN missense mutants destabilize the destruction complex
- S45 mutants of beta-catenin aren't phosphorylated
- repression of WNT target genes
- beta-catenin independent WNT signaling
- deletions in the AMER1 gene destabilize the destruction complex
- Ca2+ pathway
- AMER1 mutants destabilize the destruction complex
- TCF dependent signaling in response to WNT
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- Signaling by WNT in cancer
- Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)
|
|
|
|
|
CSTA and CTSH |
cystatin A (stefin A) |
cathepsin H |
|
- MHC class II antigen presentation
- Adaptive Immune System
|
|
|
|
|
CSTB and CTSH |
cystatin B (stefin B) |
cathepsin H |
|
- MHC class II antigen presentation
- Adaptive Immune System
|
|
|
|
|